BridgeBio Pharma Inc vs Tractor Supply Co — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Tractor Supply Co trades at $35.38 (market cap $18.05B). The key difference: BridgeBio Pharma Inc and Tractor Supply Co are close in size by market cap, and Tractor Supply Co pays a 2.77% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TSCO | |
|---|---|---|
Market Cap | $16.61B | $18.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $62.65 |
52-Week Low | $47.29 | $29.14 |
Enterprise Value | $18.16B | $24.36B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
TSCO trades at $34.56, up 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings misses and a lowered 2026 outlook reflect cyclical headwinds, though the stock remains supported by a 48% buy rating from analysts and a $36.29 consensus price target. Cash flow from operations remains strong at $1.64B for 2025, but net cash flow was negative due to investments and financing activities.
The outlook is mixed: valuation reset and insider buying signal confidence, but weak discretionary demand and cost pressures pose near-term risks. Long-term opportunities exist from digital growth and pet initiatives, yet investors face volatility from earnings uncertainty and macroeconomic sensitivity.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →